SCHEMBL5065266

SCHEMBL5065266

CSc1ncc2cc(-c3cc(NC(=O)Nc4cc(C(C)(C)C)no4)c(F)cc3Cl)c(=O)n(C)c2n1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BRAF P15056 5/20 0.46
RAF1 P04049 4/20 0.46
KDR P35968 4/20 0.46
KRAS P01116 3/20 0.46
MAP2K2 P36507 3/20 0.46
MAP2K1 Q02750 3/20 0.46
MAPK14 Q16539 10/20 0.45
MAPK13 O15264 1/20 0.39
ALDH1A1 P00352 1/20 0.37
FGFR1 P11362 1/20 0.35
NTRK1 P04629 1/20 0.35
RET P07949 1/20 0.35
EPHB2 P29323 1/20 0.35
ABL1 P00519 2/20 0.34
PDGFRB P09619 1/20 0.34
SRC P12931 1/20 0.34
PDGFRA P16234 1/20 0.34
RIPK2 O43353 1/20 0.34
NOD2 Q9HC29 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5061818 0.94 BRAF (0.44) BRAFRAF1KDRKRASMAP2K2
SCHEMBL5062732 0.92 BRAF (0.54) BRAFRAF1KDRKRASMAP2K2
SCHEMBL4277108 0.89 MAPK14 (0.44) BRAFRAF1KDRKRASMAP2K2
SCHEMBL4419689 0.89 BRAF (0.59) BRAFRAF1KDRKRASMAP2K2
SCHEMBL5057666 0.87 BRAF (0.46) BRAFRAF1KDRMAPK14MAPK13
SCHEMBL5062481 0.87 BRAF (0.61) BRAFRAF1KDRKRASMAP2K2
SCHEMBL4415318 0.87 BRAF (0.45) BRAFRAF1KDRKRASMAP2K2
SCHEMBL4426093 0.86 MAPK14 (0.46) BRAFRAF1KDRMAPK14MAPK13
SCHEMBL4279468 0.86 BRAF (0.52) BRAFRAF1KDRKRASMAP2K2
SCHEMBL4552742 0.85 RAF1 (0.41) BRAFRAF1KDRMAP2K2MAP2K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-11-15 US disclosed
US-8188113-B2 For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies DECIPHERA PHARMACEUTICALS, INC. (US) 2012-05-29 US disclosed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES BRAF, PRKDC, RAF1 BRAF 1/4885RAF1 3/4885KDR 500/4885
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 BRAF 1/4885RAF1 3/4885KDR 500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.